ProCE Banner Activity

ENGOT-EN6-NSGO/GOG-3031/RUBY: PROs With Addition of Dostarlimab to  Carboplatin/Paclitaxel for Advanced or Recurrent Endometrial Cancer

Capsule Summary
Slideset

The addition of dostarlimab to carboplatin/paclitaxel maintained patients’ health-related quality of life while improving PFS in primary advanced or recurrent endometrial cancer.

Released: June 09, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, GSK, and Merck Sharp & Dohme Corp.

AstraZeneca

GSK

Merck Sharp & Dohme Corp.